Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chimeric Antigen Receptor Therapy
Carl H. June, Michel Sadelain
New England Journal of Medicine (2018) Vol. 379, Iss. 1, pp. 64-73
Open Access | Times Cited: 1850

Showing 1-25 of 1850 citing articles:

Development of therapeutic antibodies for the treatment of diseases
Ruei‐Min Lu, Yu‐Chyi Hwang, I-Ju Liu, et al.
Journal of Biomedical Science (2020) Vol. 27, Iss. 1
Open Access | Times Cited: 1734
Cancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O’Donnell, Michele W.L. Teng, Mark J. Smyth
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 3, pp. 151-167
Closed Access | Times Cited: 1426
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
Hongyi Li, Yang Yang, Weiqi Hong, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1379
NK cells for cancer immunotherapy
Noriko Shimasaki, Amit Jain, Dario Campana
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 3, pp. 200-218
Closed Access | Times Cited: 963
Advances in immunotherapy for hepatocellular carcinoma
Bruno Sangro, Pablo Sarobe, Sandra Hervás‐Stubbs, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 8, pp. 525-543
Open Access | Times Cited: 931
Mechanisms of resistance to CAR T cell therapy
Nirali N. Shah, Terry J. Fry
Nature Reviews Clinical Oncology (2019)
Open Access | Times Cited: 836
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Jennifer N. Brudno, James N. Kochenderfer
Blood Reviews (2018) Vol. 34, pp. 45-55
Open Access | Times Cited: 753
Enhancing cancer immunotherapy with nanomedicine
Darrell J. Irvine, Eric L. Dane
Nature reviews. Immunology (2020) Vol. 20, Iss. 5, pp. 321-334
Open Access | Times Cited: 678
CD8+ T cell differentiation and dysfunction in cancer
Mary Philip, Andrea Schietinger
Nature reviews. Immunology (2021) Vol. 22, Iss. 4, pp. 209-223
Open Access | Times Cited: 671
Long-term outcomes following CAR T cell therapy: what we know so far
Kathryn M. Cappell, James N. Kochenderfer
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 6, pp. 359-371
Open Access | Times Cited: 624
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Emma Morris, Sattva S. Neelapu, Theodoros Giavridis, et al.
Nature reviews. Immunology (2021) Vol. 22, Iss. 2, pp. 85-96
Open Access | Times Cited: 616
The future of cancer immunotherapy: microenvironment-targeting combinations
Yonina R. Murciano‐Goroff, Allison Betof Warner, Jedd D. Wolchok
Cell Research (2020) Vol. 30, Iss. 6, pp. 507-519
Open Access | Times Cited: 609
Targeting cardiac fibrosis with engineered T cells
Haig Aghajanian, Tōru Kimura, Joel G. Rurik, et al.
Nature (2019) Vol. 573, Iss. 7774, pp. 430-433
Open Access | Times Cited: 571
Intratumoral heterogeneity in cancer progression and response to immunotherapy
Ilio Vitale, Efrat Shema, Sherene Loi, et al.
Nature Medicine (2021) Vol. 27, Iss. 2, pp. 212-224
Closed Access | Times Cited: 567
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Andréas Mackensen, Fabian Müller, Dimitrios Mougiakakos, et al.
Nature Medicine (2022) Vol. 28, Iss. 10, pp. 2124-2132
Closed Access | Times Cited: 554
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Marco Ruella, Jun Xu, David M. Barrett, et al.
Nature Medicine (2018) Vol. 24, Iss. 10, pp. 1499-1503
Open Access | Times Cited: 534
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
Mohamad Hamieh, Anton Dobrin, Annalisa Cabriolu, et al.
Nature (2019) Vol. 568, Iss. 7750, pp. 112-116
Open Access | Times Cited: 518
Clinical lessons learned from the first leg of the CAR T cell journey
Robbie G. Majzner, Crystal L. Mackall
Nature Medicine (2019) Vol. 25, Iss. 9, pp. 1341-1355
Closed Access | Times Cited: 518
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Joerg Herrmann
Nature Reviews Cardiology (2020) Vol. 17, Iss. 8, pp. 474-502
Open Access | Times Cited: 517
Macrophage-Based Approaches for Cancer Immunotherapy
Nicholas R. Anderson, Nicholas G. Minutolo, Saar Gill, et al.
Cancer Research (2020) Vol. 81, Iss. 5, pp. 1201-1208
Open Access | Times Cited: 497
Clinical implications of T cell exhaustion for cancer immunotherapy
Andrew Chow, Karlo Perica, Christopher A. Klebanoff, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 12, pp. 775-790
Open Access | Times Cited: 497
Monocyte heterogeneity and functions in cancer
Claire Olingy, Huy Q. Dinh, Catherine C. Hedrick
Journal of Leukocyte Biology (2019) Vol. 106, Iss. 2, pp. 309-322
Open Access | Times Cited: 461
The cancer–natural killer cell immunity cycle
Nicholas D. Huntington, Joseph Cursons, Jai Rautela
Nature reviews. Cancer (2020) Vol. 20, Iss. 8, pp. 437-454
Closed Access | Times Cited: 443
Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
Yuying Liu, Yiliang Fang, Xinfeng Chen, et al.
Science Immunology (2020) Vol. 5, Iss. 43
Open Access | Times Cited: 435
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Katrin Mestermann, Theodoros Giavridis, Justus Weber, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 499
Open Access | Times Cited: 412
Page 1 - Next Page

Scroll to top